Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | 10% owner | July 25, 2025 | September 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date July 25, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | IndirectBy: Jeremy M. Sclar 2012 Irrevocable Family Trust | 2,315,111 |
Reported balance
After 2025-07-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-25 · Other · Acquired 697,674 · Balance 2,315,111 F1: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Common Shares, no par valueSEC Table I · non-derivative | IndirectBy JS Trust | 3,710,459 |
Last balance in matching sequence
After 2025-07-25 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2025-07-25 · Other · Acquired 697,674 · Balance 3,012,785 F3: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Row 3 · 2025-07-25 · Other · Acquired 697,674 · Balance 3,710,459 F4: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Tranche A Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2025-07-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-25 · Other · Disposed 697,674 · Balance 0 F1: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Tranche B Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2025-07-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-25 · Other · Disposed 697,674 · Balance 0 F3: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Tranche C Common Share Purchase WarrantsSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2025-07-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-25 · Other · Disposed 697,674 · Balance 0 F4: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Warrant to Purchase Common SharesSEC Table II · derivative / convertible security | IndirectSee footnote | 3,139,533 |
Reported balance
After 2025-07-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-07-29 · Purchase · Acquired 3,139,533 · Balance 3,139,533 F6: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance. F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. |
| Common Shares, no par valueSEC Table I · non-derivative | IndirectBy Crocker Mountain LLC | 1,155,726 |
Reported balance
Holding disclosure · report date 2025-07-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,155,726 F5: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain. |
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 65,000 |
Reported balance
Holding disclosure · report date 2025-07-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 65,000 |
Filing footnotes · ownership attribution and instrument terms
F1: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
F2: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.
F3: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
F4: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
F5: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain.
F6: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseWarrant to Purchase Common Shares · Derivative | 3,139,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 9 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,139,533 Underlying: Common Shares · 3,139,533 shares Expires not disclosed F6 · derivative.exercise_price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance. F6 · price: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance. F6 · derivative.exercise_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance. F6 · derivative.expiration_date: On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche C Common Share Purchase Warrants · Derivative | 697,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 8 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 697,674 shares Expires not disclosed F4 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F4 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F4 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche B Common Share Purchase Warrants · Derivative | 697,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 7 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 697,674 shares Expires not disclosed F3 · derivative.exercise_price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F3 · derivative.exercise_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F3 · derivative.expiration_date: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherTranche A Common Share Purchase Warrants · Derivative | 697,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · derivative · entry 6 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 697,674 shares Expires not disclosed F1 · derivative.exercise_price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F1 · derivative.exercise_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F1 · derivative.expiration_date: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 3 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By JS Trust Disclosed balance after: 3,710,459 F4 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F4 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 2 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By JS Trust Disclosed balance after: 3,012,785 F3 · kind: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F3 · price: On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 25, 2025 Filed Sep 8, 2025 20:10 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | OtherCommon Shares, no par value | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-088246 · tm2522972-1_4seq1.xml · nonDerivative · entry 1 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: Jeremy M. Sclar 2012 Irrevocable Family Trust Disclosed balance after: 2,315,111 F1 · kind: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F1 · price: On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share. F2 · ownership.nature: Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionSeries 2 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · derivative · entry 9 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.exercise_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.expiration_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F4 · ownership.nature: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionSeries 2 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · derivative · entry 8 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.exercise_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · derivative.expiration_date: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche C Common Share Purchase Warrants · Derivative | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · derivative · entry 7 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 697,674 Underlying: Common Shares · 697,674 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.exercise_price: Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · price: Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · derivative.exercise_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.exercise_date: Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F1 · derivative.expiration_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F7 · derivative.expiration_date: Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche B Common Share Purchase Warrants · Derivative | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · derivative · entry 6 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 697,674 Underlying: Common Shares · 697,674 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.exercise_price: Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · price: Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.exercise_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.exercise_date: Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F6 · derivative.expiration_date: Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseTranche A Common Share Purchase Warrants · Derivative | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · derivative · entry 5 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 697,674 Underlying: Common Shares · 697,674 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.exercise_price: Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · price: Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.exercise_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.exercise_date: Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F1 · derivative.expiration_date: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F5 · derivative.expiration_date: Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionCommon Shares, no par value | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · nonDerivative · entry 3 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Crocker Mountain LLC Disclosed balance after: 1,155,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F4 · ownership.nature: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | ConversionCommon Shares, no par value | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · nonDerivative · entry 2 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By JS Trust Disclosed balance after: 1,617,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F3 · price: The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:15 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares, no par value | 697,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-085369 · tm2420441-3_4seq1.xml · nonDerivative · entry 1 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: Jeremy M. Sclar 2012 Irrevocable Family Trust Disclosed balance after: 1,467,437 F1 · kind: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F1 · price: On July 31, 2024, the Jeremy M. Sclar 2012 Irrevocable Family Trust acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement (the "Offering") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit. F2 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| December 04, 2023 Filed Jan 2, 2024 19:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseSeries 2 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-000270 · tm2333203-2_4seq1.xml · derivative · entry 4 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: JS Trust Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F5 · security: The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $14 million. F6 · derivative.exercise_price: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F3 · price: On December 4, 2023, the issuer entered into a Share Exchange Agreement with the holders of the issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the 9,000,000 Series 1 Preferred Shares held were exchanged for 150,000 Series 2 Preferred Shares, convertible, at the option of the holder, at any time and from time to time, into an aggregate of 150,000 Common Shares in accordance with the terms of the Series 2 Preferred Shares. F6 · derivative.exercise_date: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F6 · derivative.expiration_date: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F7 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| December 04, 2023 Filed Jan 2, 2024 19:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | SaleSeries 1 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-000270 · tm2333203-2_4seq1.xml · derivative · entry 3 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: Jeremy M. Sclar 2012 Irrevocable Family Trust Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · security: The Series 1 Preferred Shares were nonvoting and noninterest bearing and were convertible at a 60:1 ratio into Common Shares at the option of the holder. The Series 1 Preferred Shares would involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $30 million. F2 · derivative.exercise_price: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F3 · price: On December 4, 2023, the issuer entered into a Share Exchange Agreement with the holders of the issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the 9,000,000 Series 1 Preferred Shares held were exchanged for 150,000 Series 2 Preferred Shares, convertible, at the option of the holder, at any time and from time to time, into an aggregate of 150,000 Common Shares in accordance with the terms of the Series 2 Preferred Shares. F2 · derivative.exercise_date: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F2 · derivative.expiration_date: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F7 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
| December 04, 2023 Filed Jan 2, 2024 19:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseSeries 2 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-000270 · tm2333203-2_4seq1.xml · derivative · entry 2 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: Crocker Mountain Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F5 · security: The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $14 million. F6 · derivative.exercise_price: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F3 · price: On December 4, 2023, the issuer entered into a Share Exchange Agreement with the holders of the issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the 9,000,000 Series 1 Preferred Shares held were exchanged for 150,000 Series 2 Preferred Shares, convertible, at the option of the holder, at any time and from time to time, into an aggregate of 150,000 Common Shares in accordance with the terms of the Series 2 Preferred Shares. F6 · derivative.exercise_date: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F6 · derivative.expiration_date: 150,000 Common Shares underlying 150,000 Series 2 Preferred Shares, each convertible into 1 Common Share in accordance with the terms of the Series 2 Preferred Shares. F4 · ownership.nature: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain. Read SEC document |
| December 04, 2023 Filed Jan 2, 2024 19:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | SaleSeries 1 Preferred Shares, no par value · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-000270 · tm2333203-2_4seq1.xml · derivative · entry 1 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: Crocker Mountain LLC Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · security: The Series 1 Preferred Shares were nonvoting and noninterest bearing and were convertible at a 60:1 ratio into Common Shares at the option of the holder. The Series 1 Preferred Shares would involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $30 million. F2 · derivative.exercise_price: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F3 · price: On December 4, 2023, the issuer entered into a Share Exchange Agreement with the holders of the issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the 9,000,000 Series 1 Preferred Shares held were exchanged for 150,000 Series 2 Preferred Shares, convertible, at the option of the holder, at any time and from time to time, into an aggregate of 150,000 Common Shares in accordance with the terms of the Series 2 Preferred Shares. F2 · derivative.exercise_date: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F2 · derivative.expiration_date: 150,000 Common Shares underlying 9,000,000 Series 1 Preferred Shares, each initially convertible into 1 Common Share in accordance with the terms of the Series 1 Preferred Shares, and, as a result of a 60:1 stock split (the "Stock Split") of the issuer that occurred in June 2022, became convertible into an aggregate of 150,000 Common Shares. F4 · ownership.nature: Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain. Read SEC document |
| October 11, 2022 Filed Jan 2, 2024 19:45 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseWarrants to Purchase Common Shares, no par value · Derivative | 26,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-000270 · tm2333203-2_4seq1.xml · derivative · entry 5 Sclar Jeremy M. · CIK 0001955608 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By: JS Trust Disclosed balance after: 26,217 Underlying: Common Stock · 26,217 shares Expires not disclosed F8 · derivative.exercise_price: Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first become exercisable. These warrants were inadvertently omitted from Mr. Sclar's Form 3 filed on September 5, 2023. F8 · price: Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first become exercisable. These warrants were inadvertently omitted from Mr. Sclar's Form 3 filed on September 5, 2023. F8 · derivative.exercise_date: Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first become exercisable. These warrants were inadvertently omitted from Mr. Sclar's Form 3 filed on September 5, 2023. F8 · derivative.expiration_date: Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first become exercisable. These warrants were inadvertently omitted from Mr. Sclar's Form 3 filed on September 5, 2023. F7 · ownership.nature: Held through the Jeremy M. Sclar 2012 Irrevocable Family Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts ("JS Trust"). Mr Sclar's spouse is one of the trustees of the JS Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.